Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC

Academic Article
Publication Date:
2023
Short description:
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC / Naigeon, M., Dugage, M.R., Danlos, F.-X., Boselli, L., Jouniaux, J.-M., Oliveira, C.D., Ferrara, R., Duchemann, B., Berthot, C., Girard, L., Flippot, R., Albiges, L., Farhane, S., Saulnier, P., Lacroix, L., Griscelli, F., Roman, G., Hulett, T., Marabelle, A., Cassard, L., et al.. - In: SCIENCE ADVANCES. - ISSN 2375-2548. - 9:45(2023). [10.1126/sciadv.adh0708]
abstract:
Circulating senescent CD8+ T (T8sen) cells are characterized by a lack of proliferative capacities but retain cytotoxic activity and have been associated to resistance to immunotherapy in patients with advanced non–small cell lung cancer (aNSCLC). We aimed to better characterize T8sen and to determine which factors were associated with their accumulation in patients with aNSCLC. Circulating T8sen cells were characterized by a higher expression of SA-βgal and the transcription factor T-bet, confirming their senescent status. Using whole virome profiling, cytomegalovirus (CMV) was the only virus associated with T8sen. CMV was necessary but not sufficient to explain high accumulation of T8sen (T8senhigh status). In CMV+ patients, the proportion of T8sen cells increased with cancer progression. Last, CMV-induced T8senhigh phenotype but not CMV seropositivity itself was associated with worse progression-free and overall survival in patients treated with anti–PD-(L)1 therapy but not with chemotherapy. Overall, CMV is the unique viral driver of T8sen-driven resistance to anti–PD-(L)1 antibodies in patients with aNSCLC.
Iris type:
1.1 Articolo in rivista
List of contributors:
Naigeon, M.; Dugage, M. R.; Danlos, F. -X.; Boselli, L.; Jouniaux, J. -M.; Oliveira, C. D.; Ferrara, R.; Duchemann, B.; Berthot, C.; Girard, L.; Flippot, R.; Albiges, L.; Farhane, S.; Saulnier, P.; Lacroix, L.; Griscelli, F.; Roman, G.; Hulett, T.; Marabelle, A.; Cassard, L.; Besse, B.; Chaput, N.
Authors of the University:
FERRARA ROBERTO
Handle:
https://iris.unisr.it/handle/20.500.11768/176600
Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/176600/307186/sciadv.adh0708.pdf
Published in:
SCIENCE ADVANCES
Journal
  • Overview

Overview

URL

https://www.science.org/doi/10.1126/sciadv.adh0708
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.7.2.0